Aradigm, Inhale, Bioject Update Investors at Annual Drug

                         Delivery Forum 
                                 November 18 

  FOSTER CITY, Nov. 2 /PRNewswire/ -- Biotechnology stocks are broadly 
resurgent again, and the drug-delivery group is no exception.  The Third 
Annual Informed Investors Bay Area Drug Delivery Stocks Forum on November 18 
offers investors a full update on companies in this group.  
The Forum features companies like Aradigm (Nasdaq: ARDM) and 
Bioject Medical Technologies, Inc. (Nasdaq: BJCT), which are developing 
alternatives for conventional, needle delivery.  It also gives investors a 
broad look at the group, from inhaleable-insulin developer 
Inhale Therapeutics (Nasdaq: INHL) with a market capitalization of 
$2.3 billion, to tiny, emulsion-delivery firm Sonus, sporting a $6 million 
market capitalization.  
The Forum runs from 8:30 a.m. to 12:30 p.m. Saturday, November 18 at the 
Crowne Plaza Hotel in Foster City.  The cost is $25 prepaid, $40 at the door. 
More information and registration can be found at or 
by calling 800-992-4683.  
Aradigm Corporation is a developer of advanced pulmonary drug delivery 
systems for the treatment of systemic conditions as well as lung diseases. 
Aradigm's principal product development programs are based on its AERx 
Pulmonary Drug Delivery System, which creates aerosols from liquid drug 
formulations for delivery locally to the lung or systemically via the lung.  
Inhale, located in San Carlos, Calif., is pioneering drug delivery systems 
to deliver easily a range of inhaleable drugs.  Inhale now has four partnered 
development projects that are in clinical testing.  They are inhaleable forms 
of drugs used to treat diabetes, multiple sclerosis, osteoporosis and 
Bioject Medical Technologies Inc. develops, manufactures and markets jet 
injection systems for needle-free drug delivery.  Bioject's two core products 
are the Biojector 2000 and the Vitajet.  The Biojector 2000 system is a CO2 
cartridge that delivers doses of medication through the skin.  The Vitajet 
serves a similar function as the Biojector, but is powered by a spring rather 
than CO2. is the conduit for unfiltered communication between 
individual investors and the executives of technology and biotechnology 
companies.  Live virtual and onsite Forums, special webcasts, original 
editorial pieces and widely followed weekly radio shows, "BioTalk" and "Tech 
Check," put individual investors in the analyst's chair. 

-0-                             11/02/2000  
/CONTACT:  Brian Finnigan or Steve Chanecka, both of, 916-780-6100, or 800-992-4683/  
/Web site:  
CO:; Aradigm Corporation; Bioject Medical Technologies,  
 Inc.; Inhale Therapeutics 
ST:  California 
-0- Nov/02/2000 20:59 GMT
Press spacebar to pause and continue. Press esc to stop.